Randy M. Windreich, M.D.

  • Clinical Director, Division of Blood and Marrow Transplantation and Cellular Therapies
  • Associate Professor, Pediatrics, University of Pittsburgh School of Medicine
  • Director, Pediatric Hematology/Oncology/BMT Outpatient Clinic
  • Fellowship Director, Division of Blood and Marrow Transplantation and Cellular Therapies, UPMC Children's Hospital of Pittsburgh

Dr. Randy Windreich joined the faculty of the Division of Blood and Marrow Transplantation and Cellular Therapies in 2011 as an assistant professor of pediatrics in the University of Pittsburgh School of Medicine.

Dr. Windreich has played an integral role in transplant protocol development, treatment algorithms, and general BMT guidelines development. In addition to his clinical research endeavors, he also set about developing a fellowship program in pediatric blood and marrow transplantation at the UPMC Children’s Hospital of Pittsburgh, which he helped bring to fruition in 2012 as Associate Fellowship Director and was promoted to Fellowship Director in 2017.

Dr. Windreich has incorporated a clinical and translational research component to the one-year fellowship program, which has led to publications and presentations at national conferences. Dr. Windreich is also active in the CHP Pediatric Thyroid Center and is the Director of the Pediatric Hematology/Oncology/BMT Outpatient Clinic at the Children's Hospital of UPMC.

Dr. Windreich's area of clinical expertise is hematopoietic stem cell transplantation for high-risk hematologic malignancies.

Major Lectureships and Seminars

  • “Blood and Marrow Transplantation Nuts and Bolts,” oral presentation, Pediatric Hematology/Oncology Fellowship Conference, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA., September 2016
  • “Pediatric Hematology/Oncology and Blood and Marrow Transplantation: 2016 Updates: Transition and Growth,” oral presentation, Katie Swaney Foundation Board Meeting, Pittsburgh, Pa., October 2016
  • “Leukemias and Lymphomas,” oral presentation, Pediatric Residency Conference, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA., December 2016
  • “Neuroblastoma,” oral presentation, APHON Foundations and CPHON Review Course, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pa., March 2017
  • “Solid Tumors,” oral presentation, APHON Foundations and CPHON Review Course, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pa., March 2017
  • “Pediatric Cancer: Solid Tumors,” oral presentation, Pediatric Residency Conference, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA., April 2017
  • “Safety and feasibility of granulocyte transfusion for high-risk allogeneic stem cell transplant recipients,” poster presentation, American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting, Montreal, Quebec, Canada, April 2017
  • “Germ Cell Tumors,” oral presentation, Pediatric Hematology/Oncology Fellowship Conference, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA., June 2017
  • "Cardiac Complications during Blood and Marrow Transplantation,” oral presentation, Association of Pediatric Hematology/Oncology Nurses (APHON) Blood and Marrow Transplantation Course, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pa., June 2017

Professional Affiliations/Society Memberships

  • American Society of Pediatric Hematology/Oncology
  • ASBMT
  • American Society of Hematology
  • Children’s Oncology Group

Teaching Activities

The faculty members in the pediatric BMT&CT division were actively involved in teaching residents and fellows. The BMT&CT Fellowship Program (Windreich, director) established an educational environment to train advanced practice fellows in BMT in 2012. Barnum and Windreich mentored pediatric fellows. Byersdorfer mentored four medical students and one undergraduate. Carella was on lead for BMT to help design and implement the curriculum for the APP fellowship program.

Education & Training

  • Fellowship: University of Pittsburgh School of Medicine, Pittsburgh, PA
  • Residency: Inova Fairfax Hospital for Children, Falls Church, VA
  • MD: Sackler School of Medicine, Tel Aviv, Israel
  • BA: University of Pennsylvania, Philadelphia, PA

Representative Publications

Research Interests

Randy Windreich’s clinical research focused on hematopoietic stem cell transplantation for acute leukemias; using drug pharmacokinetics and pharmacodynamics to individualize and optimize therapy, particularly within the pediatric BMT patient population; and alternative uses for hematopoietic stem cells.

A Phase II Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. The objective of this study is to determine the safety and preliminary efficacy of achieving acceptable rates of event-free survival at 6 months in pediatric patients receiving a myeloablative or reduced-intensity preparative regimen prior to HSCT for high-risk acute myeloid leukemia and myelodysplastic syndrome. Developing an institutional protocol for a dual-arm myeloablative and reduced-intensity transplant conditioning for hematologic malignancies with unrelated donors, with emphasis on acute myeloid leukemia and acute lymphoblastic leukemia, will expand eligibility for HSCT, particularly for those with serious pre-transplant comorbidities. Subject enrollment continued.

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Transendocardial Injection of Ixmyelocel-T in Subjects with Heart Failure Due to Ischemic Dilated Cardiomyopathy. This was an industry-sponsored, multicenter study through Vericel Corporation (formerly Aastrom Biosciences) (Ann Arbor, Mich.), in collaboration with the UPMC Heart and Vascular Institute at UPMC Presbyterian Hospital. The objective of this study was to assess the efficacy, safety, and tolerability of ixmyelocel-T compared to placebo (vehicle control) when administered via transendocardial catheter-based injections to subjects with end-stage heart failure due to ischemic dilated cardiomyopathy who have no reasonable revascularization options (either surgical or percutaneous interventional) likely to provide clinical benefit. Results have been published in Lancet (2016;387:2412-21), reporting transendocardial delivery of ixmyelocel-T in patients with heart failure and reduced ejection fraction due to ischemic dilated cardiomyopathy resulted in a significant reduction in adjudicated clinical cardiac events and improved outcomes. An open label extension was active for patients who had been randomly assigned to receive placebo during the study period to now have the opportunity to undergo bone marrow harvest again and receive ixmyelocel-T therapy.

A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD. This was an industry-sponsored multicenter study through Mesoblast international Sarl (Switzerland). The objective of this study was to evaluate the efficacy and gather additional information on the safety of remestemcel-L in pediatric patients with Grades B-D acute graft-versus-host disease (GVHD) who have failed to respond to steroid treatment post-allogeneic HSCT. Subject enrollment continued.

Division